Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the effects of two new anticancer drugs,
erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung
cancer.
Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of
non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of
cutaneous T-cell lymphoma. This combination of drugs is experimental.
Phase:
Phase 2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center Konstantin Dragnev